• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …

Multiple guidelines and consensus papers have addressed the role of antithrombotic
strategies in patients with established coronary artery disease (CAD). Since evidence and …

Abstract Aim The “2024 aha/acc/acs/asnc/hrs/sca/scct/scmr/svm Guideline for Perioperative
Cardiovascular Management for Noncardiac Surgery” provides recommendations to guide …

Antiplatelet therapy (APT) is the foundation of treatment and prevention of atherothrombotic
events in patients with atherosclerotic cardiovascular disease. Selecting the optimal APT …

Coronary artery disease (CAD) is one of the leading causes of death globally, and
antiplatelet therapy is crucial for both its prevention and treatment. Antiplatelet drugs such as …

Importance Patients with high bleeding risk (HBR) have a poor prognosis, and it is not
known if they may benefit from complete revascularization after myocardial infarction (MI) …

Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y12 receptor inhibitor is the
standard antithrombotic treatment after percutaneous coronary interventions (PCI). Several …

Background Several trials demonstrated that aspirin monotherapy compared with aspirin
plus clopidogrel is associated with a lower incidence of bleeding without an increased risk of …

Antiplatelet therapy after percutaneous coronary intervention (PCI) has been changing in
parallel with the development of drug-eluting stents (DES) and antiplatelet agents. The …